Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential[E8]

From the notice

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to experimental antivirals for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. Candidate antiviral therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope: Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of antivirals targeting conserved viral or host mechanisms would provide a critical preparedness measure against future health threats caused by (re)emerging infectious disease epidemics or pandemics, due to infectious disease epidemics or pandemics. This topic contributes to strengthening the Research and Innovation ecosystem within the EU and su…[E3]

• Open toUniversities and research. Tagged by SLETOR from the listing's own words.
• ConditionEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• RiskThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• UnknownWe read the funder's listing, not the full guidance or application forms.

1. Bidding opened · 29 Oct 2026, 07:41 UTC

   The funder published the call with a future closing date.

   Changed: status, notice type, published at (source record Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05))

2. First seen · 28 Oct 2026, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   Source record: Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05)

Every fact on this page comes from the funder's listing. Each entry shows the record and the field it was read from.

1. E1

   The funder is European Commission.

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/type/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/deadlineDate/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed…”

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/descriptionByte/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/type/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

5. E5

   This is an EU call for proposals.

   “31094502”

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/status/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/startDate/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/status/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

8. E8

   The notice is titled "Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential".

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/title/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   From Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), field /metadata/budgetOverview/0, read 29 Oct 2026, 07:41 UTC · source ↗ (opens in a new tab)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Data licence: Creative Commons Attribution 4.0 (European Commission) ↗ (opens in a new tab). Personal contact details in notices are not stored or shown.